Cette page a été traduite automatiquement et l'exactitude de la traduction n'est pas garantie. Veuillez vous référer au version anglaise pour un texte source.

Prospective Evaluation of HIV Patients Using Non-invasive Methods for Estimation of Liver Fibrosis and Steatosis (Prospec-HIV)

15 février 2019 mis à jour par: Oswaldo Cruz Foundation

Prospective Evaluation of HIV Infected Patients Followed at Evandro Chagas National Institute of Infectious Disease (INI) - Oswaldo Cruz Foundation (FIOCRUZ) Using Non-invasive Methods for Estimation of Liver Fibrosis and Steatosis

Human immunodeficiency virus (HIV) infection is a major global health issue with up to 40 million people infected worldwide. Due to highly active antiretroviral therapy, mortality related to acquired immunodeficiency syndrome (AIDS) has been reducing in the last decades. However, liver disease remains as an important cause of severe complications and death.

Hepatic fibrosis progression is the main responsible for liver-related outcomes in HIV-positive patients. Co-infection by hepatitis B (HBV) or hepatitis C virus (HCV) is highly prevalence in HIV patients. Chronic viral co-infection induces faster liver fibrosis progression compared to mono-infected HIV. However, published data have been reporting presence of significant liver fibrosis in HIV without HBV or HCV infection. This might be related to direct action of HIV in hepatocytes or association with others factors, such as non-alcoholic fatty liver disease (NAFLD). NAFLD is associated with metabolic factors, such as obesity and type-2 diabetes mellitus. However, antiretroviral drugs may induce abnormal body fat distribution (lipodistrophy) and insulin resistance playing an important role on this process. Liver biopsy has been historically considered as the gold standard to evaluate liver injury. However, this painful method presents several limitations. Therefore, several non-invasive methods for estimation of liver fibrosis, such as biomarkers (APRI, FIB-4, FibroTest and FibroMeter) and transient elastography by Fibroscan, have been developed as an alternative to liver biopsy. The diagnostic performance and prognostic value of biomarkers and transient elastography have been validated in patients with chronic liver diseases. However, few data are available in HIV patients, especially in those without chronic viral co-infection.

Therefore, patients, medical doctors and scientific community will be beneficiated by the future application of non-invasive methods for estimation of liver injury in clinical practice in HIV patients.

Aperçu de l'étude

Description détaillée

In HIV-positive patients with or without chronic viral hepatitis co-infection, the primary aims of this project are: (i) to estimate the prevalence and incidence of liver injury (including progression of fibrosis, necro-inflammatory activity and steatosis) and to report the normal values of non-invasive methods in HIV population; (ii) to validate the diagnostic performance of non-invasive methods using a method without a gold standard (Latent Class Analysis); (iii) to validate the prognostic value of non-invasive markers to predict overall mortality and liver-related outcomes and (iv) to correlate liver injury with nutritional status. The secondary aim will be the constitution of a cohort of HIV patients, with or without chronic viral hepatitis co-infection for long-term follow-up of severe outcomes.

This prospective cohort study has been approved by the Local Ethical Committee (CAAE: 32889514.4.0000.5262) and it has been enrolling patients from June 2015 at the Evandro Chagas National Institute of Infectious Diseases - Oswaldo Cruz Foundation (INI - FioCruz), Rio de Janeiro, Brazil. A total of 2,000 patients will be included in this study during the next 5 years. This project aims to report the prevalence and incidence of liver disease in a representative sample of HIV patients with and without chronic viral hepatitis co-infection. In addition, the risk factors associated to presence and progression of liver fibrosis and steatosis will be identified and an innovative non-invasive management for estimation of liver injury in HIV patients will be validated.

Patients have been submitted at the same day to the following procedures: (i) clinical examination (anthropometric and demographic characteristics), (ii) blood sample collection (for blood analysis, calculation of biomarkers and stockage of samples), (iii) transient elastography (with M and XL probes by a single experienced operator (>2,000 examinations) and (iv) nutritional status (bioelectrical impedance and 24h diet recall).

Type d'étude

Observationnel

Inscription (Anticipé)

2000

Contacts et emplacements

Cette section fournit les coordonnées de ceux qui mènent l'étude et des informations sur le lieu où cette étude est menée.

Lieux d'étude

    • Rio De Janeiro/RJ
      • Rio de Janeiro, Rio De Janeiro/RJ, Brésil, 21040-360
        • Recrutement
        • Evandro Chagas National Institute of Infectious Diseases

Critères de participation

Les chercheurs recherchent des personnes qui correspondent à une certaine description, appelée critères d'éligibilité. Certains exemples de ces critères sont l'état de santé général d'une personne ou des traitements antérieurs.

Critère d'éligibilité

Âges éligibles pour étudier

18 ans et plus (Adulte, Adulte plus âgé)

Accepte les volontaires sains

Non

Sexes éligibles pour l'étude

Tout

Méthode d'échantillonnage

Échantillon de probabilité

Population étudiée

Patients infected by HIV with or without chronic viral hepatitis

La description

Inclusion Criteria:

  • HIV infection
  • Age >= 18 years

Exclusion Criteria:

  • Auto-immune hepatitis
  • Primary biliary cirrhosis
  • Primary sclerosing cirrhosis
  • Extra-hepatic cholestasis
  • Acute viral hepatitis
  • Hepatic ischemia
  • Hepatic metastasis

Plan d'étude

Cette section fournit des détails sur le plan d'étude, y compris la façon dont l'étude est conçue et ce que l'étude mesure.

Comment l'étude est-elle conçue ?

Détails de conception

  • Modèles d'observation: Cohorte
  • Perspectives temporelles: Éventuel

Que mesure l'étude ?

Principaux critères de jugement

Mesure des résultats
Description de la mesure
Délai
Evaluation of stage of fibrosis and grade of steatosis in patients infected by HIV
Délai: change of fibrosis stage and steatosis grade from baseline at 5 years
Staging of liver fibrosis and quantification of steatosis using non-invasive methods and correlation with risk factors
change of fibrosis stage and steatosis grade from baseline at 5 years

Mesures de résultats secondaires

Mesure des résultats
Description de la mesure
Délai
Prognostic value of non-invasive methods
Délai: up to 5 years
Evaluation of the prognostic value of non-invasive methods for prediction of severe outcomes and mortality
up to 5 years
Prevalence of liver fibrosis
Délai: up to 3 years
Estimation of liver fibrosis by non-invasive methods
up to 3 years
Prevalence of liver steatosis
Délai: up to 3 years
Estimation of liver steatosis by non-invasive methods
up to 3 years
Diagnostic performance of non-invasive methods
Délai: up to 3 years
Evaluation of diagnostic accuracy (sensitivity and specificity) of non-invasive methods using the Latent Class Analysis
up to 3 years
Nutritional status
Délai: From date of inclusion until the date of first documented alteration on nutritional status, assessed up to 5 years
Evaluation of the nutritional status by bioelectrical impedance and 24h diet recall
From date of inclusion until the date of first documented alteration on nutritional status, assessed up to 5 years
Progression of liver fibrosis
Délai: From date of inclusion until the date of first documented progression of liver fibrosis, assessed up to 5 years
Estimation of liver fibrosis by non-invasive methods
From date of inclusion until the date of first documented progression of liver fibrosis, assessed up to 5 years
Progression of liver steatosis
Délai: From date of inclusion until the date of first documented progression of liver steatosis, assessed up to 5 years
Estimation of liver steatosis by non-invasive methods
From date of inclusion until the date of first documented progression of liver steatosis, assessed up to 5 years

Collaborateurs et enquêteurs

C'est ici que vous trouverez les personnes et les organisations impliquées dans cette étude.

Les enquêteurs

  • Chercheur principal: Valdilea G Veloso, PhD, Oswaldo Cruz Foundation
  • Chercheur principal: Beatriz Grinsztejn, PhD, Oswaldo Cruz Foundation

Publications et liens utiles

La personne responsable de la saisie des informations sur l'étude fournit volontairement ces publications. Il peut s'agir de tout ce qui concerne l'étude.

Dates d'enregistrement des études

Ces dates suivent la progression des dossiers d'étude et des soumissions de résultats sommaires à ClinicalTrials.gov. Les dossiers d'étude et les résultats rapportés sont examinés par la Bibliothèque nationale de médecine (NLM) pour s'assurer qu'ils répondent à des normes de contrôle de qualité spécifiques avant d'être publiés sur le site Web public.

Dates principales de l'étude

Début de l'étude

1 juin 2015

Achèvement primaire (Anticipé)

1 mai 2020

Achèvement de l'étude (Anticipé)

1 mai 2022

Dates d'inscription aux études

Première soumission

27 août 2015

Première soumission répondant aux critères de contrôle qualité

2 septembre 2015

Première publication (Estimation)

4 septembre 2015

Mises à jour des dossiers d'étude

Dernière mise à jour publiée (Réel)

18 février 2019

Dernière mise à jour soumise répondant aux critères de contrôle qualité

15 février 2019

Dernière vérification

1 février 2018

Plus d'information

Ces informations ont été extraites directement du site Web clinicaltrials.gov sans aucune modification. Si vous avez des demandes de modification, de suppression ou de mise à jour des détails de votre étude, veuillez contacter register@clinicaltrials.gov. Dès qu'un changement est mis en œuvre sur clinicaltrials.gov, il sera également mis à jour automatiquement sur notre site Web .

S'abonner